Gladius Capital Management LP Supernus Pharmaceuticals, Inc. Transaction History

Gladius Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$22.72 - $29.68 $7,043 - $9,200	310 Added 32.46%	1,265 $36,000
Q3 2023 Dec 18, 2023	BUY	$27.57 - $32.91 $6,616 - $7,898	240 Added 33.57%	955 $26,000
Q3 2023 Oct 10, 2023	BUY	$27.57 - $32.91 $6,616 - $7,898	240 Added 33.57%	955 $27,000
Q2 2023 Dec 18, 2023	SELL	$29.91 - $38.73 $7,178 - $9,295	-240 Reduced 25.13%	715 $21,000
Q2 2023 Aug 08, 2023	BUY	$29.91 - $38.73 $21,385 - $27,691	715 New	715 $22,000
Q4 2022 Dec 18, 2023	BUY	$31.09 - $37.88 $1,989 - $2,424	64 Added 6.7%	1,019 $36,000
Q4 2022 Feb 02, 2023	SELL	$31.09 - $37.88 $777 - $947	-25 Reduced 2.39%	1,019 $37,000
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $30,056 - $36,968	1,044 New	1,044 $36,000

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.06B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.